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Introduction
•41.6% of college students reported depression as
a concern
•24.5% reported taking psychotropic medications
•SAD begins in the fall months and peaks in the
winter months due to a decrease in Vitamin D and
ultraviolet (UV) ray exposure from the sun.
•Seasonal affective disorder is synonymously used
with the terminology seasonal depression due to
clinical manifestation similarity.
•Clinical Manifestations include:
•Low energy
•Feelings of sadness, loneliness, and/or emptiness
•Fleeting or persistent hopelessness

PICO Question
In college students (ages 18-25) with seasonal
affective disorder (SAD), how does SSRI (Selective
Serotonin Reuptake Inhibitor) therapy compared to
light therapy affect seasonal affective disorder?
P: college students with SAD
I: SSRI therapy
C: Light Therapy
O: Improvement with SAD

Figure #1

Methods

Literature Review

Conclusion

• Over 20 articles resulted from searching the
keywords: light therapy, seasonal affective
disorder, SSRI
• Articles within this review were required to match
keywords and be published on or after January 1,
2017
• Databases such as CINAHL, PubMed, NLM, Gale
Academic Library, and the American Journal of
Psychiatry were utilized when conducting the
literature review
• 11 articles were selected that fell into this criteria
• Articles that did not pertain to the aforementioned
criteria were excluded

Ultraviolet Light Therapy
Ultraviolet (UV) light therapy, or Bright Light
Therapy (BLT) has been a proven, inexpensive
effective approach for the treatment of SAD. 6 out of
the 11 articles solely focused on light therapy and found
that BLT corrected winter circadian rhythm delays and
increased the function of synaptic serotonin (Campbell
et al., 2017). When BLT was used simultaneously with
cognitive behavior therapy (CBT), clinical
manifestations of SAD, alongside hypersomnia,
insomnia, and social withdrawal decreased at a faster
rate (Meyerhoff et al., 2018). However, when BLT was
the primary module of treatment with SAD, remission
rates showed improvement faster than CBT alone
(Meyerhoff et al., 2018). Out of 33 participants
diagnosed with SAD, 61% reported remission of their
depression during the 4-week study period, proving that
BLT is not only effective treatment but powerful enough
to bring depression into remission (Campbell et al.,
2017).
Selective Serotonin Reuptake Inhibitors
Two randomized control trials consisted of 136
participants who either received second-generation
antidepressants (SGA) such as fluoxetine,
escitalopram, nefazodone, BLT, or a placebo
(Nussbaumer-Streit et al., 2021). A meta-analysis
showed that Fluoxetine and BLT were equally
comparable to the treatment of SAD (NussbaumerStreit et al., 2021). Another study consisted of 183
participants administered 20mg to 40mg of fluoxetine a
day compared to 300mg to 450mg of moclobemide and
concluded that fluoxetine was the first-line treatment for
SAD (Nussbaumer-Streit et al., 2021). Research
suggests continuing SGA therapy during the summer
months to prevent the sudden or rapid onset of SAD
during the fall/winter months (Nussbaumer-Streit et al.,
2018).

• BLT and SSRI therapy were both proven effective
in the treatment of SAD
• SSRIs were more effective than MAOIs
• SAD symptoms are improved with a healthy diet
and exercise
• BLT has also been proven to be successful in the
treatment of bipolar disorders and non-seasonal
depression
• Bupropion (an NDRI) is the only FDA-approved
pharmacological treatment for SAD
• Continuing SGA therapy during the spring and
summer months prevents rapid onset of SAD
during the fall and winter months
• BLT is a first-line treatment for SAD
• The pathophysiology of SAD needs to be explored
by providers and patients
• BLT can bring SAD into remission with consistent
usage

Results
• Evidence has shown that BLT is just as effective as
SSRI therapy in treatment of SAD
• Fluoxetine had a higher remission rate of 66%
compared to participants taking
moclobemide (Nussbaumer-Streit et al., 2021)

Figure #3
Minimal side effects were noted with BLT but
included
• Eye strain
• Headache
• Nausea

Figure 1. DSM-I and DSM-V criteria for diagnosis of Seasonal Affective
Disorder
(Rosenthal, 2009)

Figure #2

Figure #4

Figure 3. PET scan of the brain before, during, and
after SSRI therapy for SAD
(James et al., 2017)

Figure 2. Pathological mechanism of Seasonal Affective Disorder
(Campbell et al., 2017)

• Lifestyle changes such as increased physical
activity and balanced diet were suggested but only
found to be effective if the providing physician and
patient had a firm concept of SAD's
pathophysiology and clinical manifestations.
• Homeopathic resources, such as massages and
osteopathy were recommended but noted to be
limited in access or high in cost.

Figure 4. Overall psychological effects of BLT on mental
health disorders.
(Maruani & Geoffroy, 2019)
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PICO Question
P

Population

I

Intervention

In college students (ages 18-25) with
seasonal affective disorder (SAD), how
does SSRI (Selective Serotonin Reuptake
Inhibitor) therapy compared to light
therapy affect seasonal affective disorder?
P: college students (ages 18-25) with SAD

C

Comparison

I: SSRI therapy
C: Light Therapy

O

Outcome

O: Improvement with SAD

• Over 20 articles resulted from searching the
keywords: light therapy, seasonal affective
disorder, SSRI

• Articles within this review were required to match
keywords and be published on or after January 1,
2017

METHODS

• Databases such as CINAHL, PuBMed, NLM, Gale
Academic Library, and the American Journal of
Psychiatry were utilized when conducting the
literature review

• 11 articles were selected that fell into this criteria
• Articles that did not pertain to the aforementioned
criteria were excluded

RESULTS
• Evidence has shown that BLT is just as effective
as SSRI therapy in treatment of SAD

• Fluoxetine had a high remission rate of 66%
compared to participants taking
moclobemide (Nussbaumer-Streit et al., 2021)

• Minimal side effects were noted with BLT but
included

–Eye strain
–Headache
–Nausea
• BLT is first-line treatment in acute SAD episodes

Figure 3. PET scan of the brain before, during, and
(James et al., 2017)
after SSRI therapy for SAD

CONCLUSIONS
• BLT and SSRI therapy were both
proven effective in the treatment of
SAD

• SSRIs were more effective than
MAOIs

• SAD symptoms are improved with a
healthy diet and exercise

• BLT has also been proven to be
successful in the treatment of bipolar
disorders and non-seasonal
depression

• No evidence has been linked to
preventing SAD

• Bupropion (an NDRI) is the only
FDA-approved pharmacological
treatment for SAD

• Continuing SGA therapy during the
spring and summer months prevents
rapid onset of SAD during the fall
and winter months

• BLT is a first-line treatment for SAD
• The pathophysiology of SAD needs
to be explored by providers and
patients

• BLT can bring SAD into remission
with consistent usage
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